6月11日，科伦博泰生物盘中下跌3.34%，报388.2港元，成交额5014.49万港元。板块层面，生物科技行业今日整体承压，百济神州跌2.94%、康方生物跌2.9%、三生制药跌2.55%、信达生物跌1.61%，创新药资产延续调整态势。
个股层面，公司此前披露的业绩显示净亏损扩大至3.82亿元，授权及里程碑收入大幅缩减、研发费用高企为主要拖累，同时董事长连续减持信号持续压制短期市场信心。尽管多家券商近日维持"买入"评级且ASCO临床数据表现积极，但板块系统性走弱下个股仍难以独善其身。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.